Vident Investment Advisory’s Cellectis CLLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-17,696
Closed -$80K 1294
2022
Q1
$80K Sell
17,696
-3,833
-18% -$21.1K ﹤0.01% 1240
2021
Q4
$175K Buy
+21,529
New +$212K ﹤0.01% 1148
2021
Q3
Sell
-14,268
Closed -$221K 1168
2021
Q2
$221K Buy
+14,268
New +$240K 0.01% 1015
2020
Q4
Sell
-79,271
Closed -$1.47M 902
2020
Q3
$1.47M Sell
79,271
-5,180
-6% -$91.9K 0.07% 375
2020
Q2
$1.5M Sell
84,451
-6,860
-8% -$104K 0.08% 311
2020
Q1
$840K Sell
91,311
-5,446
-6% -$81.2K 0.06% 444
2019
Q4
$1.66M Buy
96,757
+6,793
+8% +$90.7K 0.1% 304
2019
Q3
$936K Sell
89,964
-2,570
-3% -$34.6K 0.08% 185
2019
Q2
$1.44M Buy
92,534
+10,933
+13% +$195K 0.12% 126
2019
Q1
$1.5M Sell
81,601
-2,147
-3% -$38.1K 0.08% 345
2018
Q4
$1.39M Buy
83,748
+8,252
+11% +$191K 0.08% 339
2018
Q3
$2.13M Sell
75,496
-5,031
-6% -$145K 0.08% 313
2018
Q2
$2.28M Buy
80,527
+18,730
+30% +$558K 0.09% 304
2018
Q1
$1.89M Buy
61,797
+16,788
+37% +$530K 0.08% 317
2017
Q4
$1.31M Sell
45,009
-6,533
-13% -$178K 0.06% 331
2017
Q3
$1.47M Buy
51,542
+1,561
+3% +$40.4K 0.08% 319
2017
Q2
$1.29M Sell
49,981
-1,013
-2% -$24.2K 0.11% 292
2017
Q1
$1.22M Buy
50,994
+8,496
+20% +$178K 0.12% 294
2016
Q4
$720K Buy
42,498
+17,244
+68% +$319K 0.09% 311
2016
Q3
$608K Hold
25,254
0.08% 325
2016
Q2
$672K Sell
25,254
-24,616
-49% -$722K 0.09% 333
2016
Q1
$1.37K Buy
49,870
+23,273
+88% +$561K 0.08% 340
2015
Q4
$825K Buy
+26,597
New +$807K 0.1% 327

Other funds holding CLLS

Vident Investment Advisory's CLLS Position: Q2 2022 in Review

Vident Investment Advisory sold out of Cellectis (CLLS) in Q2 2022, closing a stake of 17,696 shares — an estimated $80K sold.

Vident Investment Advisory first reported a position in CLLS in Q4 2015 and held it in 23 quarters. The position peaked at $2.28M in Q2 2018. 45 funds tracked by Wall St. Rank hold CLLS as of Q2 2022.

  • Vident Investment Advisory reported no remaining Cellectis position as of Q2 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 17,696 Cellectis shares in Q2 2022, an estimated $80K.
  • Vident Investment Advisory first reported a position in Cellectis in Q4 2015 and held it in 23 quarters.
  • Vident Investment Advisory's Cellectis position peaked at $2.28M in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Cellectis as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.